The emergence of AntibodyPlus: the future trend of antibody-based therapeutics

Author:

Zhu Yong1ORCID,Wang Shawn Shouye23,Zhou Zhaohui Sunny45,Ho Mitchell67ORCID

Affiliation:

1. Consultant for Biopharma Companies , Anaheim, CA 92808 , USA

2. Chinese Antibody Society , 955 Massachusetts Ave, #276, Cambridge, MA 02139 , USA

3. WuXi Biologics CMC Management, , 1 Cedarbrook Drive, Cranbury, NJ 08512 , USA

4. Northeastern University Department of Chemistry and Chemical Biology, , Boston, MA 02115-5000 , USA

5. Barnett Institute for Chemical and Biological Analysis, Northeastern University , Boston, MA 02115-5000 , USA

6. Center for Cancer Research, National Cancer Institute, National Institutes of Health Laboratory of Molecular Biology, , Bethesda, MD 20892 , USA

7. Center for Cancer Research, National Cancer Institute, National Institutes of Health Antibody Engineering Program, , Bethesda, MD 20892 , USA

Abstract

Abstract To date, close to 100 canonical monoclonal antibody drugs have been approved by the FDA; furthermore, a number of antibody-derived therapeutics in nontraditional formats have reached late development stages and the market, and many more are being evaluated in early-stage development. To better reflect this trend and to set up a framework for forward thinking, we herein introduce the concept of AntibodyPlus, embracing any therapeutics with an antibody component. AntibodyPlus therapeutics contain effector modules, in the form of small molecules, nucleic acids, proteins or even cells, to enhance their therapeutic activities against cancer, virus infection and other diseases. In this short review, we discuss historic perspective and current status of therapeutic antibody development, and the scope and categories of AntibodyPlus therapeutics along with their advantages, applications and challenges. We also present several examples that highlight their design principles, potentials and future trends.

Funder

Northeastern University

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Immunology,Immunology and Allergy

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3